Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/20868
Full metadata record
DC FieldValueLanguage
dc.contributor.authorYoung, Anna Rachel-
dc.contributor.authorDa Gama Duarte, Jessica-
dc.contributor.authorCoulson, Rhiannon-
dc.contributor.authorO'Brien, Megan-
dc.contributor.authorDeb, Siddhartha-
dc.contributor.authorLopata, Alex-
dc.contributor.authorBehren, Andreas-
dc.contributor.authorMathivanan, Suresh-
dc.contributor.authorLim, Elgene-
dc.contributor.authorMeeusen, Els-
dc.date2019-05-16-
dc.date.accessioned2019-06-05T01:28:44Z-
dc.date.available2019-06-05T01:28:44Z-
dc.date.issued2019-05-16-
dc.identifier.citationCancers 2019; 11(5): E682-
dc.identifier.issn2072-6694-
dc.identifier.urihttps://ahro.austin.org.au/austinjspui/handle/1/20868-
dc.description.abstractTumor antigens are responsible for initiating an immune response in cancer patients, and their identification may provide new biomarkers for cancer diagnosis and targets for immunotherapy. The general use of serum antibodies to identify tumor antigens has several drawbacks, including dilution, complex formation, and background reactivity. In this study, antibodies were generated from antibody-secreting cells (ASC) present in tumor-draining lymph nodes of 20 breast cancer patients (ASC-probes) and were used to screen breast cancer cell lines and protein microarrays. Half of the ASC-probes reacted strongly against extracts of the MCF-7 breast cancer cell line, but each with a distinct antigen recognition profile. Three of the positive ASC-probes reacted differentially with recombinant antigens on a microarray containing cancer-related proteins. The results of this study show that lymph node-derived ASC-probes provide a highly specific source of tumor-specific antibodies. Each breast cancer patient reacts with a different antibody profile which indicates that targeted immunotherapies may need to be personalized for individual patients. Focused microarrays in combination with ASC-probes may be useful in providing immune profiles and identifying tumor antigens of individual cancer patients.-
dc.language.isoeng-
dc.subjectantibody secreting cell-
dc.subjectbiomarker-
dc.subjectbreast cancer-
dc.subjectimmune profile-
dc.subjectimmunotherapy-
dc.subjectlymph node-
dc.subjectmicroarray-
dc.subjecttumor antigen-
dc.titleImmunoprofiling of Breast Cancer Antigens Using Antibodies Derived from Local Lymph Nodes.-
dc.typeJournal Article-
dc.identifier.journaltitleCancers-
dc.identifier.affiliationCancerProbe Pty Ltd, PO Box 2237, Prahran 3181, Australiaen
dc.identifier.affiliationGarvan Institute of Medical Research, St Vincent's Clinical School, Darlinghurst, NSW 2010, Australiaen
dc.identifier.affiliationConsultant Pathologist, Anatpath. 120 Gardenvale Rd, Gardenvale Melbourne 3185, Australiaen
dc.identifier.affiliationLa Trobe Institute for Molecular Science (LIMS), La Trobe University, Melbourne 3086, Australiaen
dc.identifier.affiliationOlivia Newton-John Cancer Research Institute, Heidelberg, Victoria, Australiaen
dc.identifier.affiliationSchool of Cancer Medicine, La Trobe University, Melbourne 3086, Australiaen
dc.identifier.doi10.3390/cancers11050682-
dc.identifier.orcid0000-0003-4289-5204-
dc.identifier.orcid0000-0001-5329-280X-
dc.identifier.pubmedid31100936-
dc.type.austinJournal Article-
item.grantfulltextnone-
item.openairetypeJournal Article-
item.languageiso639-1en-
item.fulltextNo Fulltext-
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.cerifentitytypePublications-
Appears in Collections:Journal articles
Show simple item record

Page view(s)

14
checked on Nov 18, 2024

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.